{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Silo Pharma, Inc."},"Symbol":{"label":"Symbol","value":"SILO"},"Address":{"label":"Address","value":"677 N WASHINGTON BLVD SUITE 3160, SARASOTA, Florida, 34236, United States"},"Phone":{"label":"Phone","value":"800-705-0120"},"Industry":{"label":"Industry","value":"Apparel"},"Sector":{"label":"Sector","value":"Consumer Discretionary"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo's two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore."},"CompanyUrl":{"label":"Company Url","value":"https://www.silopharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Eric Weisblum","title":"Chairman, President & Chief Executive Officer"},{"name":"James S. Kuo","title":"Vice President-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}